NICE rules out abatacept for arthritis patients

The rheumatoid arthritis (RA) drug abatacept is too expensive to be prescribed on the NHS, according to NICE.

In a draft single technology appraisal of the drug, released today, NICE said abatacept is as effective as the other cytokine inhibitor rituximab for RA, but costs twice as much.

Rituximab was recently approved for use with methotrexate in RA patients RA who fail to respond to other disease-modifying anti-rheumatic drugs (DMARDs).

A NICE spokesperson said: ‘Whilst recognizing the severity of the disease, the committee concluded that based on this evidence, abatacept could not be considered good use of NHS resources.’

Chief executive of the National Rheumatoid Arthritis Society Ailsa Bosworth said: ‘To deny patients abatacept is to deny people with a very aggressive and severe form of RA one more chance at controlling the disease and condemn them to a life of pain and disability.’

rachel.liddle@haymarket.com

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

NHS England to redesign GP appraisal in light of COVID-19 pandemic

NHS England to redesign GP appraisal in light of COVID-19 pandemic

GP appraisals are being redesigned to have a greater focus on wellbeing and reduced...

Primary care to lose millions in funding unless PCNs hit recruitment targets in pandemic

Primary care to lose millions in funding unless PCNs hit recruitment targets in pandemic

Hundreds of millions of pounds could be lost to primary care if primary care networks...

Practices told to prepare for 'major expansion' of flu vaccination as QOF pared back for 2020/21

Practices told to prepare for 'major expansion' of flu vaccination as QOF pared back for 2020/21

GP practices have been told to 'gear up for a major expansion of the winter flu programme'...

NHS England unveils GP contract plans for second phase of COVID-19 response

NHS England unveils GP contract plans for second phase of COVID-19 response

GPs have been told to re-start health checks and other suspended services as NHS...

More than 80% of patients report 'good' overall experience of general practice

More than 80% of patients report 'good' overall experience of general practice

Public satisfaction with GP services remains high, with 82% of patients reporting...

GPs condemn 'deafening silence' from chancellor on COVID support funding

GPs condemn 'deafening silence' from chancellor on COVID support funding

GP leaders have condemned a 'deafening silence' on COVID-19 relief funding for general...